Hims & Hers Health shares dip amid rising selling pressure

Traders Union
All News
Stocks
Hims & hers health slides 2.54% today

Highlights

Hims & Hers Health acquired Eucalyptus, expanding its preventative healthcare platform into the UK with a focus on sexual health services.
The acquisition's financial terms were undisclosed, aligning with the firm's international expansion strategy amid ongoing stock price pressures.
Technicals show strong bullish momentum with overbought signals; stock is expected to consolidate between $31.64 and $37.51, with a breakout above $35.55 possible.

Expansion into UK via Eucalyptus seen as strategic, yet faces selling pressure

Hims & Hers Health expanded into the UK by acquiring Eucalyptus, the parent company of Juniper. This deal aims to extend its preventative healthcare services to more UK patients, particularly in sexual health. The financial details of the acquisition have not been disclosed, and this action is part of its global growth strategy, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, views the recent Hims & Hers Health pullback as a warning sign despite the company's UK expansion via the Eucalyptus acquisition. He notes that overbought technical readings — especially the RSI and Stochastic RSI — point to a heightened risk of a near-term reversal. The reliance on bullish momentum appears fragile with the long-term structure still bearish and persistent selling pressure after the news. Kharitonov stresses caution, citing the stock's sensitivity to exhaustion signals and possible corrections below $33.36. "Extreme overbought signals and an unresolved longer-term downtrend mean I'd remain defensive until technical confirmation of renewed upside appears."

Viktoras Karapetjanc, expert at Traders Union, highlights the significance of Hims & Hers Health's entry into the UK through the Eucalyptus deal. He believes the move strengthens the company's global footprint and widens its opportunities in preventative healthcare, bolstering the overall bullish setup. The structure remains constructive with price action buoyed above major moving averages and momentum signals supportive of further growth. Karapetjanc remains confident that the market offers upside setups, especially on breaks above $35.55. "Expansion into new markets lays the foundation for future rallies — I expect consolidation here to lead to additional gains in the coming weeks."

Parshwa Turakhiya, analyst, notes sentiment around Hims & Hers Health remains strong after the Eucalyptus acquisition, though volatility is high. He sees price holding near the upper range, with aggressive buying despite the recent gap down. Technical indicators are heavily stretched, so risk of a short-term pullback is real, yet opportunities exist both for breakout traders above $35.55 and for mean-reversion setups if the price dips under $33.36. "For now, traders should watch both sides — momentum favors breakouts, but quick reversals are likely if overbought readings start unwinding."

Bullish momentum persists amid technical resistance and stretched overbought signals

Hims & Hers Health is trading above its 20-day, 50-day, and 200-day moving averages ($27.7, $26.64, and $33.36, respectively), reflecting bullish momentum across all time frames. Price action is currently supported by the Ichimoku Kijun at $28.54, with a near-term resistance at $35.55 and support at $33.36. However, the alignment between the 50-day and 200-day moving averages suggests the long-term structure remains bearish. Momentum indicators are stretched, with MACD and ADX forecasting more upside, yet RSI at 71.08, Stochastic RSI at 100, and CCI at 231.5 each flag intense overbought conditions. Bull/Bear Power at 5.93 confirms buyer dominance, and the Awesome Oscillator affirms the bullish tilt. After a sharp downside gap of $2.63 (approximately 7.41%), HIMS sits near the upper end of the daily range with high intraday volatility. Despite the sustained upward pressure post-gap and strength in momentum signals, these overbought indicators warn of possible near-term exhaustion.

Earlier, analysts noted that Hims & Hers Health's acquisition of Eucalyptus was expected to intensify its international growth narrative and sustain bullish momentum. The current price action, marked by persistent overbought signals and elevated volatility, highlights the importance of monitoring for a potential near-term exhaustion despite ongoing upside risk.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.